Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early quadruple therapy with lobeglitazone and empagliflozin in uncontrolled type 2 diabetes on metformin and DPP4 inhibitors
KCT0007323Phase 3Not yet recruiting
- Sponsor
- Chong Kun Dang
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lobeglitazone, empagliflozin, metformin in type 2 diabetes mellitus (T2DM), sponsored by Chong Kun Dang. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
lobeglitazoneempagliflozinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on KCT0007323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007323.